Literature DB >> 33956908

Correction: Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0234103.].

Entities:  

Year:  2021        PMID： 33956908      PMCID： PMC8101907          DOI： 10.1371/journal.pone.0251671

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


  1 in total

1.  Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

Authors:  Sheelagh Frame; Chiara Saladino; Craig MacKay; Butrus Atrash; Peter Sheldrake; Edward McDonald; Paul A Clarke; Paul Workman; David Blake; Daniella Zheleva
Journal:  PLoS One       Date:  2020-07-09       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.